Minoo Ahmadinejad Explores Emicizumab
Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:
”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.
Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.
Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.
The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.
Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”

Stay updated with Hemostasis Today.
-
Nov 19, 2026, 07:00Rucha Patil: Highlights in Science and Collaboration at Haematocon 2026
-
Nov 19, 2026, 06:20Suvro Sankha Datta: AABB Releases the 8th Edition of Molecular Testing Standards
-
Nov 19, 2026, 05:54Global Collaboration in Hemostasis – ISTH
-
Nov 19, 2026, 05:40Pete Stibbs: Advancing Treatment Strategies in Venous Disease
-
Nov 19, 2026, 05:31Lance Reed: One Donation, Multiple Lives
-
Nov 19, 2026, 05:20ZPI Silencing as a Novel Non-Factor Therapy for Rare Bleeding Disorders – HITh
-
Nov 19, 2026, 04:48Antiphospholipid Antibodies and Stroke Management – RPTH
-
Nov 18, 2026, 20:58Uma Vaidyanathan: When Hemoglobin Does Not Respond to Iron Therapy, Look Beyond Iron Deficiency
-
Nov 18, 2026, 20:57Jamil Rafiq: 5 Ways to Prevent Sample Haemolysis